 Home > Active Ingredient News > Blood System > JEADV: Evaluation of the efficacy of Mogamulizumab in mycosis fungoides or Sézary syndrome based on baseline blood tumor burden

JEADV: Evaluation of the efficacy of Mogamulizumab in mycosis fungoides or Sézary syndrome based on baseline blood tumor burden

 Last Update: 2021-07-27
 Source: Internet
 Author: User

Tags

depakote level

post safety caps

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The Phase 3 MAVORIC trial (NCT01728805) compared Mogamulizumab and Vorinostat in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed previous systemic treatment (≥1).

Mycosis fungoides

The purpose of this post-mortem analysis was to evaluate the impact of the underlying blood tumor burden on the patient's responsiveness to Mogamulizumab

According to the results of flow cytometry, the test patients were divided into three levels of low, medium and high tumor burden (B0[n=126], B1[n=62], B2[n=184]), and the patients in each group were evaluated PFS, ORR, time before second treatment (TTNT), skin reactivity and safety

Basic tumor burden group details

Compared with vorinostat, Mogamulizumab significantly prolonged the PFS of patients of all grades, especially those of B1 and B2 grades

Compared with vorinostat, Mogamulizumab significantly prolonged the PFS of patients in each grade, especially in patients with grades B1 and B2.

PFS of patients in the two treatment groups

The TTNT of grade B1 and B2 patients treated with Mogamulizumab was also significantly longer than that of patients treated with vorinostat (B1: 12.

The TTNT of grade B1 and B2 patients treated with Mogamulizumab was also significantly longer than that of patients treated with vorinostat.

Changes in mSWAT of patients in each grade

In the mogamulizumab treatment arm, 82 patients (43.

The CD4+CD26-cell count and CD4:CD8 ratio of patients treated with Mogamulizumab in each group decreased rapidly and continuously

In summary, this post-mortem analysis showed that for patients with MF and SS classified as B1 and B2 blood involvement, Mogamulizumab has greater clinical benefit than vorinostat

For patients with MF and SS classified as B1 and B2 blood involvement, Mogamulizumab has greater clinical benefit than vorinostat.

Original source:

Cowan R,Scarisbrick JJ,Zinzani PL et al.

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.